AstraZeneca Financials

Market Capitalization £170.96 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	31.91
Forward PE	15.07
Price to Sales TTM	£3.34
Price to Book MRQ	£414.19
Enterprise to Revenue	3.79
Enterprise to EBITDA	10.55

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	12.68%
Operating Margin	20.40%
Return on Assets TTM	8.50%
Return on Equity TTM	16.66%

Income Statement

Revenue TTM	£41,788,191,466
Revenue per Share TTM	£33.04
Quarterly Revenue Growth	18.00%
Gross Profit TTM	£34,519,365,658
EBITDA	£15,598,000,000
Net Income to Common TTM	£5,300,439,457
Diluted EPS TTM	£3.41
Quarterly Earnings Growth YoY	4.00%

Balance Sheet

Total Cash MRQ	£4,023,274,147
Total Cash per Share MRQ	£3.18
Total Debt MRQ	£
Total Debt to Equity MRQ	77.47
Current Ratio MRQ	0.93
Book Value per Share MRQ	£26.27

Cash Flow

Operating Cash Flow TTM	£9,249,450,066
Levered Free Cash Flow TTM	£7,758,676,438

AZN Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	1,550,550,016
Float Shares	1,544,528,500
Avg 10 Volume	2,205,850
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	0.04%
% Held by Institutions	52.24%

Stock Price Summary

Beta	0.18
Fifty Two Week Low	£9461.00
Fifty Two Week High	£13388.00
Fifty Two Week Change	4.36%
Day 50 MA	£10469.64
Day 200 MA	£11703.16

Dividends and Splits

Forward Annual Dividend Rate	£155.20
Forward Annual Dividend Yield	1.40%
Trailing Annual Dividend Rate	£233.60
Trailing Annual Dividend Yield	2.11%
Payout Ratio	72.14%
Dividend Date
Ex Dividend Date	2024-08-08
Last Split Factor
Last Split Date